Phase II study of alemtuzumab in chronic lymphoproliferative disorders-Reference-Cited by-同舟云学术

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

Published:2003-08-01 Issue:4 Volume:98 Page:773-778
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ferrajoli Alessandra,O'Brien Susan M.,Cortes Jorge E.,Giles Francis J.,Thomas Deborah A.,Faderl Stefan,Kurzrock Razelle,Lerner Susan,Kontoyiannis Dimitrios P.,Keating Michael J.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference23 articles.

1. Reshaping human antibodies for therapy

2. The CAMPATH-1 antigen (CDw52)

3. Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells

4. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H

5. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maladies générales, médicaments et fonction thyroïdienne;Les Maladies de la Thyroïde;2022

2. Cytomegalovirus in Haematological Tumours;Frontiers in Immunology;2021-10-18

3. The immune-related gene CD52 is a favorable biomarker for breast cancer prognosis;Gland Surgery;2021-02

4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma;Journal for ImmunoTherapy of Cancer;2020-12

5. Current Development of Monoclonal Antibodies in Cancer Therapy;Current Immunotherapeutic Strategies in Cancer;2019-09-01